Abstract
Background: Drug metabolites are generally more soluble, achieve lower concentrations in human plasma and can be excreted more easily than their parent drugs. Accordingly, drug metabolites are rarely characterized comprehensively in preclinical models and their on- and off-target activity is often overlooked. However, drug metabolites can play significant roles in the efficacy and safety of their parent dugs and help us explain clinical observations. Four PARP inhibitors have been approved by the FDA as cancer therapeutics, namely, olaparib, rucaparib, niraparib and talazoparib.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
